Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.

2.

Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion.

Roix JJ, DeCrescenzo GA, Cheung PH, Ciallella JR, Sulpice T, Saha S, Halse R.

Diabetes Obes Metab. 2012 Apr;14(4):329-34. doi: 10.1111/j.1463-1326.2011.01529.x. Epub 2011 Dec 27.

PMID:
22059694
3.

Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.

Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J.

J Med Chem. 2010 Sep 23;53(18):6653-80. doi: 10.1021/jm100669j.

PMID:
20726512
4.

MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.

Kolodziej SA, Hockerman SL, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Stehle N, Swearingen C, Becker DP.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3561-4. doi: 10.1016/j.bmcl.2010.04.111. Epub 2010 Apr 28.

PMID:
20529685
5.

Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.

Kolodziej SA, Hockerman SL, Boehm TL, Carroll JN, DeCrescenzo GA, McDonald JJ, Mischke DA, Munie GE, Fletcher TR, Rico JG, Stehle NW, Swearingen C, Becker DP.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3557-60. doi: 10.1016/j.bmcl.2010.04.130. Epub 2010 May 23.

PMID:
20529684
6.

Physiochemical drug properties associated with in vivo toxicological outcomes.

Hughes JD, Blagg J, Price DA, Bailey S, Decrescenzo GA, Devraj RV, Ellsworth E, Fobian YM, Gibbs ME, Gilles RW, Greene N, Huang E, Krieger-Burke T, Loesel J, Wager T, Whiteley L, Zhang Y.

Bioorg Med Chem Lett. 2008 Sep 1;18(17):4872-5. doi: 10.1016/j.bmcl.2008.07.071. Epub 2008 Jul 24.

PMID:
18691886
7.

Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy.

Becker DP, Villamil CI, Barta TE, Bedell LJ, Boehm TL, Decrescenzo GA, Freskos JN, Getman DP, Hockerman S, Heintz R, Howard SC, Li MH, McDonald JJ, Carron CP, Funckes-Shippy CL, Mehta PP, Munie GE, Swearingen CA.

J Med Chem. 2005 Oct 20;48(21):6713-30.

PMID:
16220987
8.

Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols.

Freskos JN, Mischke BV, DeCrescenzo GA, Heintz R, Getman DP, Howard SC, Kishore NN, McDonald JJ, Munie GE, Rangwala S, Swearingen CA, Voliva C, Welsch DJ.

Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.

PMID:
10230616
9.

Inhibitors of HIV-1 protease containing the novel and potent (R)-(hydroxyethyl)sulfonamide isostere.

Vazquez ML, Bryant ML, Clare M, DeCrescenzo GA, Doherty EM, Freskos JN, Getman DP, Houseman KA, Julien JA, Kocan GP, et al.

J Med Chem. 1995 Feb 17;38(4):581-4. No abstract available.

PMID:
7861404
10.

Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere.

Getman DP, DeCrescenzo GA, Heintz RM, Reed KL, Talley JJ, Bryant ML, Clare M, Houseman KA, Marr JJ, Mueller RA, et al.

J Med Chem. 1993 Jan 22;36(2):288-91. No abstract available.

PMID:
8423599

Supplemental Content

Loading ...
Support Center